{"id":33701,"date":"2025-10-14T16:27:48","date_gmt":"2025-10-14T10:57:48","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=33701"},"modified":"2025-10-15T08:54:58","modified_gmt":"2025-10-15T03:24:58","slug":"pharma-news-for-boehringer-denali-regeneron","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-boehringer-denali-regeneron","title":{"rendered":"FDA Approves Boehringer\u2019s JASCAYD as First New IPF Therapy in Over a Decade; Denali Therapeutics&#8217; Tividenofusp Alfa BLA Review for Hunter Syndrome Extended by FDA; Bicara\u2019s Ficerafusp Alfa Earns FDA Breakthrough Tag for 1L HPV-Negative Head &amp; Neck Cancer; BeOne Medicines\u2019 Sonrotoclax Granted FDA Breakthrough Designation for Cancer Treatment; FDA Clears LIBTAYO for Adjuvant Use in Cutaneous Squamous Cell Carcinoma"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69deb153b7a7a\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69deb153b7a7a\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-boehringer-denali-regeneron\/#FDA_Approves_Boehringers_JASCAYD_as_First_New_IPF_Therapy_in_Over_a_Decade\" >FDA Approves Boehringer\u2019s JASCAYD as First New IPF Therapy in Over a Decade<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-boehringer-denali-regeneron\/#Denali_Therapeutics_Tividenofusp_Alfa_BLA_Review_for_Hunter_Syndrome_Extended_by_FDA\" >Denali Therapeutics&#8217; Tividenofusp Alfa BLA Review for Hunter Syndrome Extended by FDA<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-boehringer-denali-regeneron\/#Bicaras_Ficerafusp_Alfa_Earns_FDA_Breakthrough_Tag_for_1L_HPV-Negative_Head_and_Neck_Cancer\" >Bicara\u2019s Ficerafusp Alfa Earns FDA Breakthrough Tag for 1L HPV-Negative Head and Neck Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-boehringer-denali-regeneron\/#BeOne_Medicines_Sonrotoclax_Granted_FDA_Breakthrough_Designation_for_Cancer_Treatment\" >BeOne Medicines\u2019 Sonrotoclax Granted FDA Breakthrough Designation for Cancer Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-boehringer-denali-regeneron\/#LIBTAYO_Approved_in_US_as_First_and_Only_Adjuvant_Immunotherapy_for_High-Risk_CSCC_Post-Surgery_and_Radiation\" >LIBTAYO Approved in U.S. as First and Only Adjuvant Immunotherapy for High-Risk CSCC Post-Surgery and Radiation<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-boehringer-s-jascayd-as-first-new-ipf-therapy-in-over-a-decade\"><span class=\"ez-toc-section\" id=\"FDA_Approves_Boehringers_JASCAYD_as_First_New_IPF_Therapy_in_Over_a_Decade\"><\/span>FDA Approves Boehringer\u2019s JASCAYD as First New IPF Therapy in Over a Decade<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Boehringer Ingelheim\u2019s JASCAYD (nerandomilast)<\/strong> has received FDA approval as an oral treatment for <a href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-market\">adults with <strong>idiopathic pulmonary fibrosis (IPF)<\/strong><\/a><strong>,<\/strong> marking the first new therapy for the condition in over a decade. JASCAYD is the first and only preferential PDE4B inhibitor approved for IPF, offering a novel mechanism that delivers both antifibrotic and immunomodulatory effects to slow lung function decline.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis milestone represents a new era in the treatment of IPF, a rare and debilitating chronic condition that worsens lung function,\u201d said Dr. Toby Maher, Professor of Clinical Medicine at the Keck School of Medicine, USC. \u201cNerandomilast is a welcome new treatment option with a well-tolerated safety profile for physicians to consider for appropriate patients.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Approval is supported by results from two clinical trials, FIBRONEER-IPF (NCT05321069) and Trial 2 (NCT04419506). In the phase III FIBRONEER-IPF study, nerandomilast significantly reduced the decline in Forced Vital Capacity (FVC) at week 52 compared to placebo. Patients on nerandomilast 18 mg and 9 mg showed mean declines of -106 mL and -122 mL, respectively, versus -170 mL in the placebo group.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe FDA approval of nerandomilast is a pivotal moment for people living with IPF,\u201d said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. \u201cThis new step forward, driven by the compelling results of the FIBRONEER-IPF trial, underscores our unwavering commitment to change the way we treat IPF.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>The most common adverse events (\u22655%) included diarrhea, upper respiratory infections, depression, and decreased appetite, with higher rates of discontinuation seen in the nerandomilast groups compared to placebo. However, the product label includes no \u2018Warnings and Precautions\u2019 section. \u201cThere has been a long-standing need for new treatment options for IPF,\u201d added Scott Staszak, President and CEO of the Pulmonary Fibrosis Foundation. \u201cNerandomilast provides an important addition to the care landscape.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-denali-therapeutics-tividenofusp-alfa-bla-review-for-hunter-syndrome-extended-by-fda\"><span class=\"ez-toc-section\" id=\"Denali_Therapeutics_Tividenofusp_Alfa_BLA_Review_for_Hunter_Syndrome_Extended_by_FDA\"><\/span>Denali Therapeutics&#8217; Tividenofusp Alfa BLA Review for Hunter Syndrome Extended by FDA<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Denali Therapeutics<\/strong> announced that the FDA has extended the review timeline for its Biologics License Application (BLA) seeking accelerated approval of tividenofusp alfa for <a href=\"https:\/\/www.delveinsight.com\/report-store\/mucopolysaccharidosis-ii-market\"><strong>mucopolysaccharidosis type II (MPS II)<\/strong><\/a>, also known as <a href=\"https:\/\/www.delveinsight.com\/report-store\/hunter-syndrome-market\"><strong>Hunter syndrome<\/strong><\/a><strong>. <\/strong>The Prescription Drug User Fee Act (PDUFA) date has been moved from January 5, 2026, to April 5, 2026.<\/p>\n\n\n\n<p>The extension follows Denali\u2019s submission of updated clinical pharmacology data in response to an FDA request. The agency classified the submission as a Major Amendment (MA), which, per standard procedure, triggered a three-month review extension. The company noted that the amendment does not affect the clinical pharmacology or benefit-risk profile of the BLA, and no new data were requested.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe appreciate the FDA\u2019s continued collaboration throughout the review process,\u201d said Ryan Watts, Ph.D., CEO of Denali Therapeutics. \u201cWe continue to prepare for the potential approval and commercial launch of tividenofusp alfa. We feel the urgency to deliver for the MPS community.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Tividenofusp alfa is being evaluated as a potential first-in-class therapy for MPS II, a rare genetic disorder with significant unmet medical need. Denali remains engaged with regulatory authorities and stakeholders as it advances toward a possible FDA decision in 2026.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-bicara-s-ficerafusp-alfa-earns-fda-breakthrough-tag-for-1l-hpv-negative-head-and-neck-cancer\"><span class=\"ez-toc-section\" id=\"Bicaras_Ficerafusp_Alfa_Earns_FDA_Breakthrough_Tag_for_1L_HPV-Negative_Head_and_Neck_Cancer\"><\/span>Bicara\u2019s Ficerafusp Alfa Earns FDA Breakthrough Tag for 1L HPV-Negative Head and Neck Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Bicara Therapeutics<\/strong> announced that the FDA has granted Breakthrough Therapy Designation (BTD) to ficerafusp alfa in combination with pembrolizumab for first-line treatment of patients with<strong> <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/head-and-neck-squamous-cell-carcinoma-market\"><strong>metastatic or unresectable, recurrent head and neck squamous cell carcinoma (HNSCC)<\/strong><\/a><strong> <\/strong>whose tumors are HPV-negative and have a PD-L1 combined positive score (CPS) \u22651.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cBTD provides external validation of the importance of ficerafusp alfa\u2019s best-in-disease potential, and solidifies the foundation for our ongoing pivotal trial, FORTIFI-HN01,\u201d said Claire Mazumdar, PhD, MBA, CEO of Bicara Therapeutics. \u201cWe look forward to working closely with the FDA to bring this therapy to patients as quickly as possible.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The designation is supported by data from multiple phase I\/Ib dose cohorts, most recently presented at the 2025 ASCO Annual Meeting. Results showed a median duration of response of 21.7 months and median overall survival of 21.3 months, with a favorable safety profile, highlighting the combination\u2019s potential to provide durable benefit in a population with limited options.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis recognition highlights the urgent unmet need for patients with HPV-negative R\/M HNSCC,\u201d added Dr. David Raben, Chief Medical Officer at Bicara. \u201cIt reinforces our conviction that the synergy between ficerafusp alfa and pembrolizumab can drive deeper, longer-lasting responses in this challenging cancer type.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-beone-medicines-sonrotoclax-granted-fda-breakthrough-designation-for-cancer-treatment\"><span class=\"ez-toc-section\" id=\"BeOne_Medicines_Sonrotoclax_Granted_FDA_Breakthrough_Designation_for_Cancer_Treatment\"><\/span>BeOne Medicines\u2019 Sonrotoclax Granted FDA Breakthrough Designation for Cancer Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>BeOne Medicines <\/strong>announced that the FDA has granted <strong>Breakthrough Therapy Designation (BTD)<\/strong> to <strong>sonrotoclax<\/strong>, its next-generation investigational BCL2 inhibitor, for the treatment of adults with <a href=\"https:\/\/www.delveinsight.com\/report-store\/mantle-cell-lymphoma-market\"><strong>relapsed or refractory (R\/R) mantle cell lymphoma (MCL)<\/strong><\/a>. In addition, the FDA has accepted BeOne\u2019s application to participate in Project Orbis, a global regulatory initiative that allows concurrent review of oncology products across multiple countries.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;Breakthrough Therapy Designation is reserved for medicines with the potential to transform outcomes for patients with serious diseases,&#8221; said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. &#8220;This recognition affirms the strength of the emerging data for sonrotoclax and its potential to become a new standard of care for people with relapsed or refractory mantle cell lymphoma.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The FDA\u2019s decisions are based on results from the ongoing Phase I\/II BGB-11417-201 study, which is evaluating sonrotoclax in R\/R MCL patients previously treated with a BTK inhibitor and anti-CD20 therapy. Topline results suggest deep and durable responses, and full data are expected at an upcoming medical meeting. A Phase III confirmatory trial, CELESTIAL-RRMCL, is currently underway.<\/p>\n\n\n\n<p>This marks the first BTD for sonrotoclax and the second for BeOne\u2019s hematology pipeline. The investigational therapy has also received Fast Track Designation and Orphan Drug Designation in MCL and other B-cell malignancies, including WM, MM, and AML, supporting BeOne\u2019s commitment to advancing care for patients with hard-to-treat blood cancers.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-libtayo-approved-in-u-s-as-first-and-only-adjuvant-immunotherapy-for-high-risk-cscc-post-surgery-and-radiation\"><span class=\"ez-toc-section\" id=\"LIBTAYO_Approved_in_US_as_First_and_Only_Adjuvant_Immunotherapy_for_High-Risk_CSCC_Post-Surgery_and_Radiation\"><\/span>LIBTAYO Approved in U.S. as First and Only Adjuvant Immunotherapy for High-Risk CSCC Post-Surgery and Radiation<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Regeneron Pharmaceuticals<\/strong> announced that the FDA has approved <strong>LIBTAYO (cemiplimab-rwlc)<\/strong> as an adjuvant treatment for adults with<strong> <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-squamous-cell-carcinoma-cscc-market\"><strong>cutaneous squamous cell carcinoma (CSCC)<\/strong><\/a><strong> <\/strong>at high risk of recurrence following surgery and radiation. This marks the first immunotherapy approved in this setting and was evaluated under Priority Review due to its potential to improve patient outcomes significantly.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis approval provides patients with CSCC at high risk of disease recurrence following surgery and radiation a much-needed option, as LIBTAYO is the only immunotherapy to demonstrate efficacy in this setting,\u201d said Dr. George D. Yancopoulos, Board co-Chair, President and Chief Scientific Officer at Regeneron. \u201cNow with five FDA-approved indications, LIBTAYO is firmly established as a strong and versatile PD-1 inhibitor for a range of cancers.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The approval is based on results from the pivotal phase III C-POST trial, which demonstrated a 68% reduction in the risk of disease recurrence or death with LIBTAYO compared to placebo (HR: 0.32; 95% CI: 0.20\u20130.51; p&lt;0.0001). The safety profile was consistent with known effects of LIBTAYO, with the most common adverse events including rash, pruritus, and hypothyroidism.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cMany patients who undergo surgical resection of their CSCC are later found to be at high risk of recurrence,\u201d noted Dr. Vishal Patel of George Washington University. \u201cAs the first and only approved adjuvant immunotherapy for these patients, LIBTAYO represents a practice-changing opportunity backed by compelling data.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>An additional regulatory decision for LIBTAYO in the European Union is expected in the first half of 2026. Regeneron also announced the launch of <strong>LIBTAYO Surround<\/strong>, a support program offering financial and educational resources to assist patients throughout their treatment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA Approves Boehringer\u2019s JASCAYD as First New IPF Therapy in Over a Decade Boehringer Ingelheim\u2019s JASCAYD (nerandomilast) has received FDA approval as an oral treatment for adults with idiopathic pulmonary fibrosis (IPF), marking the first new therapy for the condition in over a decade. JASCAYD is the first and only preferential PDE4B inhibitor approved for [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":33703,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[890,4895,4905,204,704,280,19575,303,12926,12925,651,5071,5073,5310,17738,19774,349,19103,21555,6767,420,639,5789,18026],"industry":[17225],"therapeutic_areas":[17237,17240,17228,17243],"class_list":["post-33701","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-cutaneous-squamous-cell-carcinoma","tag-cutaneous-squamous-cell-carcinoma-market","tag-cutaneous-squamous-cell-carcinoma-therapy-market","tag-delveinsight","tag-fda","tag-head-and-neck-squamous-cell-carcinoma","tag-head-and-neck-squamous-cell-carcinoma-hnscc","tag-hunter-syndrome","tag-hunter-syndrome-market","tag-hunter-syndrome-pipeline","tag-idiopathic-pulmonary-fibrosis","tag-idiopathic-pulmonary-fibrosis-market","tag-idiopathic-pulmonary-fibrosis-market-forecast","tag-idiopathic-pulmonary-fibrosis-market-landscape","tag-idiopathic-pulmonary-fibrosis-pipeline","tag-idiopathic-pulmonary-fibrosis-treatment","tag-latest-pharma-news","tag-mantle-cell-lymphoma","tag-mantle-cell-lymphoma-market","tag-mucopolysaccharidosis","tag-news","tag-pharma-news","tag-recent-pharma-news","tag-relapsed-or-refractory-mantle-cell-lymphoma","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-oncology","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Boehringer, Denali, Regeneron<\/title>\n<meta name=\"description\" content=\"Boehringer\u2019s JASCAYD; Denali\u2019s Tividenofusp Alfa; Bicara\u2019s Ficerafusp Alfa; BeOne\u2019s Sonrotoclax; Regeneron\/Sanofi\u2019s LIBTAYO\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-boehringer-denali-regeneron\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Boehringer, Denali, Regeneron\" \/>\n<meta property=\"og:description\" content=\"Boehringer\u2019s JASCAYD; Denali\u2019s Tividenofusp Alfa; Bicara\u2019s Ficerafusp Alfa; BeOne\u2019s Sonrotoclax; Regeneron\/Sanofi\u2019s LIBTAYO\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-boehringer-denali-regeneron\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-14T10:57:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-15T03:24:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/14162359\/14-10-2025-feature.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Boehringer, Denali, Regeneron","description":"Boehringer\u2019s JASCAYD; Denali\u2019s Tividenofusp Alfa; Bicara\u2019s Ficerafusp Alfa; BeOne\u2019s Sonrotoclax; Regeneron\/Sanofi\u2019s LIBTAYO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-boehringer-denali-regeneron","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Boehringer, Denali, Regeneron","og_description":"Boehringer\u2019s JASCAYD; Denali\u2019s Tividenofusp Alfa; Bicara\u2019s Ficerafusp Alfa; BeOne\u2019s Sonrotoclax; Regeneron\/Sanofi\u2019s LIBTAYO","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-boehringer-denali-regeneron","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-10-14T10:57:48+00:00","article_modified_time":"2025-10-15T03:24:58+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/14162359\/14-10-2025-feature.webp","type":"image\/webp"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-boehringer-denali-regeneron","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-boehringer-denali-regeneron","name":"Pharma News | Boehringer, Denali, Regeneron","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-boehringer-denali-regeneron#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-boehringer-denali-regeneron#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/14162359\/14-10-2025-feature.webp","datePublished":"2025-10-14T10:57:48+00:00","dateModified":"2025-10-15T03:24:58+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Boehringer\u2019s JASCAYD; Denali\u2019s Tividenofusp Alfa; Bicara\u2019s Ficerafusp Alfa; BeOne\u2019s Sonrotoclax; Regeneron\/Sanofi\u2019s LIBTAYO","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-boehringer-denali-regeneron"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-boehringer-denali-regeneron#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/14162359\/14-10-2025-feature.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/14162359\/14-10-2025-feature.webp","width":772,"height":482,"caption":"pharma-news-for-boehringer-denali-regeneron"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/14162359\/14-10-2025-feature-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cutaneous Squamous Cell Carcinoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cutaneous squamous cell carcinoma market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cutaneous squamous cell carcinoma therapy market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Head and Neck Squamous Cell Carcinoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">head and neck squamous cell carcinoma (HNSCC)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hunter syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hunter Syndrome Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hunter Syndrome Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Idiopathic Pulmonary Fibrosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Idiopathic Pulmonary fibrosis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Idiopathic Pulmonary fibrosis market forecast<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Idiopathic Pulmonary Fibrosis Market Landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Idiopathic Pulmonary Fibrosis Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">idiopathic pulmonary fibrosis treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Mantle Cell Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Mantle Cell Lymphoma Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">mucopolysaccharidosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Relapsed Or Refractory Mantle Cell Lymphoma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cutaneous Squamous Cell Carcinoma<\/span>","<span class=\"advgb-post-tax-term\">Cutaneous squamous cell carcinoma market<\/span>","<span class=\"advgb-post-tax-term\">Cutaneous squamous cell carcinoma therapy market<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Head and Neck Squamous Cell Carcinoma<\/span>","<span class=\"advgb-post-tax-term\">head and neck squamous cell carcinoma (HNSCC)<\/span>","<span class=\"advgb-post-tax-term\">Hunter syndrome<\/span>","<span class=\"advgb-post-tax-term\">Hunter Syndrome Market<\/span>","<span class=\"advgb-post-tax-term\">Hunter Syndrome Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Idiopathic Pulmonary Fibrosis<\/span>","<span class=\"advgb-post-tax-term\">Idiopathic Pulmonary fibrosis market<\/span>","<span class=\"advgb-post-tax-term\">Idiopathic Pulmonary fibrosis market forecast<\/span>","<span class=\"advgb-post-tax-term\">Idiopathic Pulmonary Fibrosis Market Landscape<\/span>","<span class=\"advgb-post-tax-term\">Idiopathic Pulmonary Fibrosis Pipeline<\/span>","<span class=\"advgb-post-tax-term\">idiopathic pulmonary fibrosis treatment<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Mantle Cell Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Mantle Cell Lymphoma Market<\/span>","<span class=\"advgb-post-tax-term\">mucopolysaccharidosis<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Relapsed Or Refractory Mantle Cell Lymphoma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 months ago","modified":"Updated 6 months ago"},"absolute_dates":{"created":"Posted on Oct 14, 2025","modified":"Updated on Oct 15, 2025"},"absolute_dates_time":{"created":"Posted on Oct 14, 2025 4:27 pm","modified":"Updated on Oct 15, 2025 8:54 am"},"featured_img_caption":"pharma-news-for-boehringer-denali-regeneron\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33701","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=33701"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33701\/revisions"}],"predecessor-version":[{"id":33713,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33701\/revisions\/33713"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/33703"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=33701"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=33701"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=33701"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=33701"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=33701"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}